ELDNNCMHealthcare·Biotechnology#300 in industry

Eledon Pharmaceuticals, Inc.

Reports in 16d· 2026-05-13

+57.3% · 90d

$3.46

-0.00 (-0.14%)

After-Hours $3.51(+0.05)

News

(1)

April 2026

Apr 21, 20266 days agoPRE 14AHealthcare

Eledon (ELDN) Shareholders Vote on 450 Million Authorized Share Increase

ELDNEledon Pharmaceuticals, Inc.

# 📝 Preliminary Proxy Statement Guide 📘 This document, a Preliminary Proxy Statement (PRE 14A), is a detailed legal filing filed with the SEC. Think of it as the comprehensive rulebook for the company's annual shareholder meeting. Its purpose is not to give financial performance, but rather to inf

Read summaryView on SEC EDGAR

Key Data

Market Cap$275.5M

Open$3.46

Prev Close$3.46

Day Range$3.35 – $3.65

52W Range$1.35 – $4.60

Volume1,551,020

P/E (TTM)—

EPS$-0.52

Dividend Yield—

Beta0.84

Price Target$8.00(+131.2%)

Next Earnings2026-05-13(16d)

Analyst Ratings

Strong Buy7 analysts

Buy 7Hold 0Sell 0

About

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Healthcare · Biotechnology

33 employees

eledon.com